Skip to main content
SpringerLink
Log in

Advances in MRI Applications to Diagnose and Manage Cardiomyopathies

  • Heart Failure (W Tang, Section Editor)
  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Abstract

Purpose of review

The prevalence of heart failure continues to rise, and imaging characterization of the cardiomyopathic process is important for identifying myocardial disease, initiating appropriate treatment, and improving outcomes. We aimed to summarize recent advances in cardiac magnetic resonance imaging (CMR) applications for the diagnosis, characterization, and implications on management of various cardiomyopathies.

Recent findings

Parametric mapping by CMR has emerged as an important advancement in quantification of myocardial fibrosis, increased extracellular space, and myocardial edema. In addition, improved assessment of myocardial function with myocardial strain assessment may provide early identification of patients at risk and determining responsiveness to therapeutic interventions. Novel MRI techniques and the advent of artificial intelligence may help to uncover important mechanistic insights into the cardiomyopathic process.

Summary

Innovative CMR techniques continue to evolve, and it will be of interest to determine how these advances can be incorporated into clinical practice to improve diagnosis, treatment, and management of patients with cardiomyopathies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association. Circulation. 2019;139:e56–e528.

    PubMed  Google Scholar 

  2. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols. J Cardiovasc Magn Reson. 2008;10:35.

    PubMed  PubMed Central  Google Scholar 

  3. Hundley WG, Bluemke D, Bogaert JG, Friedrich MG, Higgins CB, Lawson MA, et al. Society for Cardiovascular Magnetic Resonance guidelines for reporting cardiovascular magnetic resonance examinations. J Cardiovasc Magn Reson. 2009;11:5.

    PubMed  PubMed Central  Google Scholar 

  4. Isbell DC, Kramer CM. Cardiovascular magnetic resonance: structure, function, perfusion, and viability. J Nucl Cardiol. 2005;12:324–36.

    PubMed  Google Scholar 

  5. Andreu D, Penela D, Acosta J, Fernandez-Armenta J, Perea RJ, Soto-Iglesias D, et al. Cardiac magnetic resonance-aided scar dechanneling: influence on acute and long-term outcomes. Heart Rhythm. 2017;14:1121–8.

    PubMed  Google Scholar 

  6. Souto ALM, Souto RM, Teixeira ICR, Nacif MS. Myocardial viability on cardiac magnetic resonance. Arq Bras Cardiol. 2017;108:458–69.

    PubMed  PubMed Central  CAS  Google Scholar 

  7. Gulati A, Ismail TF, Ali A, Hsu LY, Goncalves C, Ismail NA, et al. Microvascular dysfunction in dilated cardiomyopathy: a quantitative stress perfusion cardiovascular magnetic resonance study. J Am Coll Cardiol Img. 2019.

  8. Piechnik SK, Ferreira VM, Dall'Armellina E, Cochlin LE, Greiser A, Neubauer S, et al. Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. J Cardiovasc Magn Reson. 2010;12:69.

    PubMed  PubMed Central  Google Scholar 

  9. Borbely A, van der Velden J, Papp Z, Bronzwaer JG, Edes I, Stienen GJ, et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation. 2005;111:774–81.

    PubMed  Google Scholar 

  10. Zile MR, Baicu CF, Ikonomidis JS, Stroud RE, Nietert PJ, Bradshaw AD, et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015;131:1247–59.

    PubMed  PubMed Central  CAS  Google Scholar 

  11. Aoki T, Fukumoto Y, Sugimura K, Oikawa M, Satoh K, Nakano M, et al. Prognostic impact of myocardial interstitial fibrosis in non-ischemic heart failure. -comparison between preserved and reduced ejection fraction heart failure. Circ J. 2011;75:2605–13.

    PubMed  CAS  Google Scholar 

  12. Broadbent DA, Biglands JD, Larghat A, Sourbron SP, Radjenovic A, Greenwood JP, et al. Myocardial blood flow at rest and stress measured with dynamic contrast-enhanced MRI: comparison of a distributed parameter model with a Fermi function model. Magn Reson Med. 2013;70:1591–7.

    PubMed  CAS  Google Scholar 

  13. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation. 2010;122:138–44.

    PubMed  Google Scholar 

  14. Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol. 2008;52:1574–80.

    PubMed  Google Scholar 

  15. Sado DM, Flett AS, Banypersad SM, White SK, Maestrini V, Quarta G, et al. Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart. 2012;98:1436–41.

    PubMed  Google Scholar 

  16. Jan MF, Tajik AJ. Modern imaging techniques in cardiomyopathies. Circ Res. 2017;121:874–91.

    PubMed  CAS  Google Scholar 

  17. Lota AS, Gatehouse PD, Mohiaddin RH. T2 mapping and T2* imaging in heart failure. Heart Fail Rev. 2017;22:431–40.

    PubMed  PubMed Central  CAS  Google Scholar 

  18. Anderson LJ, Wonke B, Prescott E, Holden S, Malcolm Walker J, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet. 2002;360:516–20.

    PubMed  CAS  Google Scholar 

  19. Greulich S, Deluigi CC, Gloekler S, Wahl A, Zurn C, Kramer U, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6:501–11.

    PubMed  Google Scholar 

  20. •• Liu Y, Hamilton J, Rajagopalan S, Seiberlich N. Cardiac magnetic resonance fingerprinting: technical overview and initial results. JACC: Cardiovascular Imaging. 2018;11:1837–53. A recent review and overview of a novel technique for comprehensive myocardial mapping (T1, T2, fat fraction) within a single breathhold.

    PubMed  Google Scholar 

  21. Hamilton JI, Jiang Y, Ma D, Chen Y, Lo W-C, Griswold M, et al. Simultaneous multislice cardiac magnetic resonance fingerprinting using low rank reconstruction. NMR Biomed. 2019;32:e4041.

    PubMed  Google Scholar 

  22. Hamilton JI, Eck B, Griswold M, Seiberlich N. Cardiac Cine Magnetic Resonance Fingerprinting (cine-MRF) for Combined Ejection Fraction, T1, and T2 Quantification. J Cardiovasc Magn Reson. 2019.

  23. Jerosch-Herold M. Techniques for MR myocardial perfusion imaging. In: Kwong RY, Jerosch-Herold M, Heydari B, editors. Cardiovascular Magnetic Resonance Imaging. New York: Springer; 2019. p. 99–112.

    Google Scholar 

  24. Merkle N, Wöhrle J, Grebe O, Nusser T, Kunze M, Kestler HA, et al. Assessment of myocardial perfusion for detection of coronary artery stenoses by steady-state, free-precession magnetic resonance first-pass imaging. Heart. 2007;93:1381–5.

    PubMed  PubMed Central  Google Scholar 

  25. Engblom H, Xue H, Akil S, Carlsson M, Hindorf C, Oddstig J, et al. Fully quantitative cardiovascular magnetic resonance myocardial perfusion ready for clinical use: a comparison between cardiovascular magnetic resonance imaging and positron emission tomography. J Cardiovasc Magn Reson. 2017;19:78.

    PubMed  PubMed Central  Google Scholar 

  26. Tezuka D, Kosuge H, Terashima M, Koyama N, Kishida T, Tada Y, et al. Myocardial perfusion reserve quantified by cardiac magnetic resonance imaging is associated with late gadolinium enhancement in hypertrophic cardiomyopathy. Heart Vessel. 2018;33:513–20.

    Google Scholar 

  27. Sourbron SP, Buckley DL. Tracer kinetic modelling in MRI: estimating perfusion and capillary permeability. Phys Med Biol. 2011;57:R1–R33.

    PubMed  Google Scholar 

  28. Valkovič L, Clarke WT, Schmid AI, Raman B, Ellis J, Watkins H, et al. Measuring inorganic phosphate and intracellular pH in the healthy and hypertrophic cardiomyopathy hearts by in vivo 7T 31P-cardiovascular magnetic resonance spectroscopy. J Cardiovasc Magn Reson. 2019;21:19.

    PubMed  PubMed Central  Google Scholar 

  29. Arani A, Arunachalam SP, Chang ICY, Baffour F, Rossman PJ, Glaser KJ, et al. Cardiac MR elastography for quantitative assessment of elevated myocardial stiffness in cardiac amyloidosis. J Magn Reson Imaging. 2017;46:1361–7.

    PubMed  PubMed Central  Google Scholar 

  30. Tran N, Giannakidis A, Gullberg GT, Seo Y. Quantitative analysis of hypertrophic myocardium using diffusion tensor magnetic resonance imaging. J Med Imaging (Bellingham, Wash). 2016;3:046001.

    Google Scholar 

  31. Ferreira PF, Kilner PJ, McGill L-A, Nielles-Vallespin S, Scott AD, Ho SY, et al. In vivo cardiovascular magnetic resonance diffusion tensor imaging shows evidence of abnormal myocardial laminar orientations and mobility in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2014;16:87.

    PubMed  PubMed Central  Google Scholar 

  32. Lakdawala NK, Winterfield JR, Funke BH. Dilated cardiomyopathy. Circ Arrhythm Electrophysiol. 2013;6:228–37.

    PubMed  Google Scholar 

  33. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.

    PubMed  Google Scholar 

  34. Mitrut R, Stepan AE, Pirici D. Histopathological aspects of the myocardium in dilated cardiomyopathy. Curr Health Sci J. 2018;44:243–9.

    PubMed  PubMed Central  CAS  Google Scholar 

  35. Iles LM, Ellims AH, Llewellyn H, Hare JL, Kaye DM, McLean CA, et al. Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. Eur Heart J Cardiovasc Imaging. 2015;16:14–22.

    PubMed  Google Scholar 

  36. Sree Raman K, Nucifora G, Leong DP, Marx C, Shah R, Woodman RJ, et al. Long term prognostic importance of late gadolinium enhancement in first-presentation non-ischaemic dilated cardiomyopathy. Int J Cardiol. 2019;280:124–9.

    PubMed  Google Scholar 

  37. Gulati A, Japp AG, Raza S, Halliday BP, Jones DA, Newsome S, et al. Absence of myocardial fibrosis predicts favorable long-term survival in new-onset heart failure. Circ Cardiovasc Imaging. 2018;11:e007722.

    PubMed  Google Scholar 

  38. Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. Jama. 2013;309:896–908.

    PubMed  CAS  Google Scholar 

  39. •• Di Marco A, Anguera I, Schmitt M, Klem I, Neilan TG, White JA, et al. Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis. JACC Heart Fail. 2017;5:28–38. A Review and meta-analysis of the current literature demonstrating the important prognostic power of late gadolinium enhancement.

    PubMed  Google Scholar 

  40. Leyva F, Foley PW, Chalil S, Ratib K, Smith RE, Prinzen F, et al. Cardiac resynchronization therapy guided by late gadolinium-enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2011;13:29.

    PubMed  PubMed Central  Google Scholar 

  41. Leyva F, Taylor RJ, Foley PW, Umar F, Mulligan LJ, Patel K, et al. Left ventricular midwall fibrosis as a predictor of mortality and morbidity after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy. J Am Coll Cardiol. 2012;60:1659–67.

    PubMed  Google Scholar 

  42. aus dem Siepen F, Buss SJ, Messroghli D, Andre F, Lossnitzer D, Seitz S, et al. T1 mapping in dilated cardiomyopathy with cardiac magnetic resonance: quantification of diffuse myocardial fibrosis and comparison with endomyocardial biopsy. Eur Heart J Cardiovasc Imaging. 2015;16:210–6.

    PubMed  Google Scholar 

  43. Puntmann VO, Carr-White G, Jabbour A, Yu CY, Gebker R, Kelle S, et al. T1-mapping and outcome in nonischemic cardiomyopathy: all-cause mortality and heart failure. JACC Cardiovasc Imaging. 2016;9:40–50.

    PubMed  Google Scholar 

  44. J Holloway C, Suttie J, Dass S, Neubauer S. Clinical Cardiac Magnetic Resonance Spectroscopy. 2011.

    PubMed  Google Scholar 

  45. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et al. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol. 2009;53:1475–87.

    PubMed  PubMed Central  Google Scholar 

  46. •• Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation. Expert Recommendations. 2018;72:3158–76 A recent review updating the current criteria for diagnosing myocarditis based on CMR findings.

    Google Scholar 

  47. Maron BJ, Maron MS. The remarkable 50 years of imaging in HCM and how it has changed diagnosis and management: from M-mode echocardiography to CMR. JACC Cardiovasc Imaging. 2016;9:858–72.

    PubMed  Google Scholar 

  48. Weng Z, Yao J, Chan RH, He J, Yang X, Zhou Y, et al. Prognostic value of LGE-CMR in HCM: a meta-analysis. JACC Cardiovasc Imaging. 2016;9:1392–402.

    PubMed  Google Scholar 

  49. Todiere G, Pisciella L, Barison A, Del Franco A, Zachara E, Piaggi P, et al. Abnormal T2-STIR magnetic resonance in hypertrophic cardiomyopathy: a marker of advanced disease and electrical myocardial instability. PLoS One. 2014;9:e111366–6.

    PubMed  PubMed Central  Google Scholar 

  50. Amano Y, Kitamura M, Takano H, Yanagisawa F, Tachi M, Suzuki Y, et al. Cardiac MR Imaging of hypertrophic cardiomyopathy: techniques, findings, and clinical relevance. Magn Reson Med Sci. 2018;17:120–31.

    PubMed  PubMed Central  Google Scholar 

  51. Muchtar E, Blauwet LA, Gertz MA. Restrictive cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121:819–37.

    PubMed  CAS  Google Scholar 

  52. •• Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132:1570–9 An important study demonstrating the utility of T1mapping, ECV quantification and late gadolinium enhacnement for the assessment of cardiac amyloidosis.

    PubMed  PubMed Central  CAS  Google Scholar 

  53. Oda S, Utsunomiya D, Morita K, Nakaura T, Yuki H, Kidoh M, et al. Cardiovascular magnetic resonance myocardial T1 mapping to detect and quantify cardiac involvement in familial amyloid polyneuropathy. Eur Radiol. 2017;27:4631–8.

    PubMed  Google Scholar 

  54. Lee GY, Kim HK, Choi JO, Chang SA, Oh JK, Jeon ES, et al. Visual assessment of relative apical sparing pattern is more useful than quantitative assessment for diagnosing cardiac amyloidosis in borderline or mildly increased left Ventricular Wall thickness. Circ J. 2015;79:1575–84.

    PubMed  CAS  Google Scholar 

  55. Puntmann VO, Isted A, Hinojar R, Foote L, Carr-White G, Nagel E. T1 and T2 mapping in recognition of early cardiac involvement in systemic sarcoidosis. Radiology. 2017;285:63–72.

    PubMed  Google Scholar 

  56. Torlasco C, Cassinerio E, Roghi A, Faini A, Capecchi M, Abdel-Gadir A, et al. Role of T1 mapping as a complementary tool to T2* for non-invasive cardiac iron overload assessment. PLoS One. 2018;13:e0192890.

    PubMed  PubMed Central  Google Scholar 

  57. Radunski U, Lund G, Säring D, Bohnen S, Stehning C, Schnackenburg B, Avanesov M, Tahir E, Adam G, Blankenberg S, Muellerleile K. T1 and T2 mapping cardiovascular magnetic resonance imaging techniques reveal unapparent myocardial injury in patients with myocarditis. 2016.

    Google Scholar 

  58. Lahm T, Douglas IS, Archer SL, Bogaard HJ, Chesler NC, Haddad F, et al. Assessment of right ventricular function in the research setting: knowledge gaps and pathways forward. An official American Thoracic Society research statement. Am J Respir Crit Care Med. 2018;198:e15–43.

    PubMed  PubMed Central  Google Scholar 

  59. Kim RJ, Wu E, Rafael A, Chen E-L, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM. The Use of Contrast-Enhanced Magnetic Resonance Imaging to Identify Reversible Myocardial Dysfunction 2000; 343: 1445–1453.

  60. Andreini D, Pontone G, Bogaert J, Roghi A, Barison A, Schwitter J, et al. Long-term prognostic value of cardiac magnetic resonance in left ventricle noncompaction: a prospective multicenter study. J Am Coll Cardiol. 2016;68:2166–81.

    PubMed  Google Scholar 

  61. Amzulescu M-S, Rousseau MF, Ahn SA, Boileau L, de Meester de Ravenstein C, Vancraeynest D, et al. Prognostic impact of Hypertrabeculation and noncompaction phenotype in dilated cardiomyopathy: a CMR study. JACC Cardiovasc Imaging. 2015;8:934–46.

    PubMed  Google Scholar 

  62. Gräni C, Eichhorn C, Bière L, Murthy VL, Agarwal V, Kaneko K, et al. Prognostic value of cardiac magnetic resonance tissue characterization in risk stratifying patients with suspected myocarditis. J Am Coll Cardiol. 2017;70:1964–76.

    PubMed  PubMed Central  Google Scholar 

  63. Bönner F, Spieker M, Haberkorn S, Jacoby C, Flögel U, Schnackenburg B, et al. Myocardial T2 mapping increases noninvasive diagnostic accuracy for biopsy-proven myocarditis. JACC Cardiovasc Imaging. 2016;9:1467–9.

    PubMed  Google Scholar 

  64. Cao Y, Zhang PY. Review of recent advances in the management of hypertrophic cardiomyopathy. Eur Rev Med Pharmacol Sci. 2017;21:5207–10.

    PubMed  CAS  Google Scholar 

  65. Weissler-Snir A, Hindieh W, Spears DA, Adler A, Rakowski H, Chan RH. The relationship between the quantitative extent of late gadolinium enhancement and burden of nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: a delayed contrast-enhanced magnetic resonance study. J Cardiovasc Electrophysiol. 2019.

  66. Mentias A, Raeisi-Giglou P, Smedira NG, Feng K, Sato K, Wazni O, et al. Late gadolinium Enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function. J Am Coll Cardiol. 2018;72:857–70.

    PubMed  Google Scholar 

  67. Vigneault DM, Yang E, Jensen PJ, Tee MW, Farhad H, Chu L, et al. Left ventricular strain is abnormal in preclinical and overt hypertrophic cardiomyopathy: cardiac MR feature tracking. Radiology. 2018;290:640–8.

    PubMed  Google Scholar 

  68. Crilley JG, Boehm EA, Blair E, Rajagopalan B, Blamire AM, Styles P, et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol. 2003;41:1776–82.

    PubMed  CAS  Google Scholar 

  69. Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, et al. Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol. 2017;70:466–77.

    PubMed  CAS  Google Scholar 

  70. Williams LK, Forero JF, Popovic ZB, Phelan D, Delgado D, Rakowski H, et al. Patterns of CMR measured longitudinal strain and its association with late gadolinium enhancement in patients with cardiac amyloidosis and its mimics. J Cardiovasc Magn Reson. 2017;19:61.

    PubMed  PubMed Central  Google Scholar 

  71. Shintani Y, Okada A, Morita Y, Hamatani Y, Amano M, Takahama H, et al. Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy. ESC Heart Failure. 2019;6:232–6.

    PubMed  Google Scholar 

  72. Ridouani F, Damy T, Tacher V, Derbel H, Legou F, Sifaoui I, et al. Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis. J Cardiovasc Magn Reson. 2018;20:58.

    PubMed  PubMed Central  Google Scholar 

  73. Kouranos V, Tzelepis GE, Rapti A, Mavrogeni S, Aggeli K, Douskou M, et al. Complementary role of CMR to conventional screening in the diagnosis and prognosis of cardiac sarcoidosis. JACC Cardiovasc Imaging. 2017;10:1437–47.

    PubMed  Google Scholar 

  74. Dweck MR, Abgral R, Trivieri MG, Robson PM, Karakatsanis N, Mani V, et al. Hybrid magnetic resonance imaging and positron emission tomography with Fluorodeoxyglucose to diagnose active cardiac sarcoidosis. JACC Cardiovasc Imaging. 2018;11:94–107.

    PubMed  Google Scholar 

  75. Leonardi B, Margossian R, Colan SD, Powell AJ. Relationship of magnetic resonance imaging estimation of myocardial iron to left ventricular systolic and diastolic function in thalassemia. JACC Cardiovasc Imaging. 2008;1:572–8.

    PubMed  Google Scholar 

  76. Kwon DH, Halley CM, Carrigan TP, Zysek V, Popovic ZB, Setser R, et al. Extent of left ventricular scar predicts outcomes in ischemic cardiomyopathy patients with significantly reduced systolic function: a delayed Hyperenhancement cardiac magnetic resonance study. JACC Cardiovasc Imaging. 2009;2:34–44.

    PubMed  Google Scholar 

  77. Kwon DH, Kusunose K, Obuchowski NA, Cavalcante JL, Popovic ZB, Thomas JD, et al. Predictors and prognostic impact of progressive ischemic mitral regurgitation in patients with advanced ischemic cardiomyopathy. Circ Cardiovasc Imaging. 2016;9:e004577.

    PubMed  Google Scholar 

  78. Kwon DH, Hachamovitch R, Adeniyi A, Nutter B, Popovic ZB, Wilkoff BL, et al. Myocardial scar burden predicts survival benefit with implantable cardioverter defibrillator implantation in patients with severe ischaemic cardiomyopathy: influence of gender. Heart. 2014;100:206–13.

    PubMed  Google Scholar 

  79. Sabe MA, Sabe SA, Kusunose K, Flamm SD, Griffin BP, Kwon DH. Predictors and prognostic significance of right ventricular ejection fraction in patients with ischemic cardiomyopathy. Circulation. 2016;134:656–65.

    PubMed  Google Scholar 

  80. Kusunose K, Obuchowski NA, Gillinov M, Popovic ZB, Flamm SD, Griffin BP, et al. Predictors of mortality in patients with severe ischemic cardiomyopathy undergoing surgical mitral valve intervention. J Am Heart Assoc. 2017;6:e007163.

    PubMed  PubMed Central  Google Scholar 

  81. Kwon DH, Asamoto L, Popovic ZB, Kusunose K, Robinson M, Desai M, et al. Infarct characterization and quantification by delayed Enhancement cardiac magnetic resonance imaging is a powerful independent and incremental predictor of mortality in patients with advanced ischemic cardiomyopathy. Circ Cardiovasc Imaging. 2014;7:796–804.

    PubMed  Google Scholar 

  82. Wilson S, Islam F, Chen DW, Chinitz J, Goyal P, Fujikura K, Nguyen T, Wang Y, Levine RA, Devereux RB, Weinsaft JW. Papillary muscle infarction in relation to left ventricular infarct distribution and transmurality - assessment by delayed enhancement cardiac magnetic resonance imaging. J Cardiovasc Magn Reson 2012; 14: P36-P36.

  83. Acosta J, Fernández-Armenta J, Borràs R, Anguera I, Bisbal F, Martí-Almor J, et al. Scar characterization to predict life-threatening arrhythmic events and sudden cardiac death in patients with cardiac resynchronization therapy: the GAUDI-CRT Study. JACC Cardiovasc Imaging. 2018;11:561–72.

    PubMed  Google Scholar 

  84. Carrick D, Haig C, Rauhalammi S, Ahmed N, Mordi I, McEntegart M, et al. Pathophysiology of LV remodeling in survivors of STEMI: inflammation, remote myocardium, and prognosis. JACC Cardiovasc Imaging. 2015;8:779–89.

    PubMed  PubMed Central  Google Scholar 

  85. Hamirani YS, Wong A, Kramer CM, Salerno M. Effect of microvascular obstruction and Intramyocardial hemorrhage by CMR on LV remodeling and outcomes after myocardial infarction: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 2014;7:940–52.

    PubMed  PubMed Central  Google Scholar 

  86. Carberry J, Carrick D, Haig C, Ahmed N, Mordi I, McEntegart M, et al. Persistent Iron within the infarct Core after ST-segment elevation myocardial infarction. Implications for Left Ventricular Remodeling and Health Outcomes. 2018;11:1248–56.

    PubMed  Google Scholar 

  87. Strijkers GJ, Bouts A, Blankesteijn WM, Peeters THJM, Vilanova A, van Prooijen MC, et al. Diffusion tensor imaging of left ventricular remodeling in response to myocardial infarction in the mouse. NMR Biomed. 2009;22:182–90.

    PubMed  Google Scholar 

  88. Miles C, Finocchiaro G, Papadakis M, Gray B, Westaby J, Ensam B, Basu J, Parry-Williams G, Papatheodorou E, Paterson C, Malhotra A, Robertus JL, Ware JS, Cook SA, Asimaki A, Witney A, Ster IC, Tome M, Sharma S, Behr ER, Sheppard MN. Sudden Death and Left Ventricular Involvement in Arrhythmogenic Cardiomyopathy. 0.

  89. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Eur Heart J. 2010;31:806–14.

    PubMed  PubMed Central  Google Scholar 

  90. Calkins H, Corrado D, Marcus F. Risk Stratification in Arrhythmogenic Right Ventricular Cardiomyopathy 2017; 136: 2068–2082.

  91. Aquaro GD, Pingitore A, Di Bella G, Piaggi P, Gaeta R, Grigoratos C, et al. Prognostic role of cardiac magnetic resonance in Arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol. 2018;122:1745–53.

    PubMed  Google Scholar 

  92. Zghaib T, Ghasabeh MA, Assis FR, Chrispin J, Keramati A, Misra S, Berger R, Calkins H, Kamel I, Nazarian S, Zimmerman S, Tandri H. Regional Strain by Cardiac Magnetic Resonance Imaging Improves Detection of Right Ventricular Scar Compared With Late Gadolinium Enhancement on a Multimodality Scar Evaluation in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy 2018; 11: e007546.

  93. Marra MP, Leoni L, Bauce B, Corbetti F, Zorzi A, Migliore F, Silvano M, Rigato I, Tona F, Tarantini G, Cacciavillani L, Basso C, Buja G, Thiene G, Iliceto S, Corrado D. Imaging Study of Ventricular Scar in Arrhythmogenic Right Ventricular Cardiomyopathy 2012; 5: 91–100.

  94. Ross SB, Jones K, Blanch B, Puranik R, McGeechan K, Barratt A, et al. A systematic review and meta-analysis of the prevalence of left ventricular non-compaction in adults. Eur Heart J. 2019.

  95. Nordin S, Kozor R, Bulluck H, Castelletti S, Rosmini S, Abdel-Gadir A, et al. Cardiac Fabry disease with late gadolinium Enhancement is a chronic inflammatory cardiomyopathy. J Am Coll Cardiol. 2016;68:1707–8.

    PubMed  Google Scholar 

  96. Moon JC, Sheppard M, Reed E, Lee P, Elliott PM, Pennell DJ. The histological basis of late gadolinium Enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson. 2006;8:479–82.

    PubMed  Google Scholar 

  97. Krämer J, Niemann M, Störk S, Frantz S, Beer M, Ertl G, et al. Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease. Am J Cardiol. 2014;114:895–900.

    PubMed  Google Scholar 

  98. Hanneman K, Karur GR, Wasim S, Morel CF, Iwanochko RM. Prognostic significance of cardiac magnetic resonance imaging late gadolinium Enhancement in Fabry disease. Circulation. 2018;138:2579–81.

    PubMed  Google Scholar 

  99. Thompson RB, Chow K, Khan A, Chan A, Shanks M, Paterson I, et al. T1 mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex. Circ Cardiovasc Imaging. 2013;6:637–45.

    PubMed  Google Scholar 

  100. Liu JM, Liu A, Leal J, McMillan F, Francis J, Greiser A, et al. Measurement of myocardial native T1 in cardiovascular diseases and norm in 1291 subjects. J Cardiovasc Magn Reson. 2017;19:74.

    PubMed  PubMed Central  Google Scholar 

  101. Pica S, Sado DM, Maestrini V, Fontana M, White SK, Treibel T, et al. Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2014;16:99–9.

  102. Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013;6:392–8.

    PubMed  Google Scholar 

  103. McGivney D, Deshmane A, Jiang Y, Ma D, Badve C, Sloan A, et al. Bayesian estimation of multicomponent relaxation parameters in magnetic resonance fingerprinting. Magn Reson Med. 2018;80:159–70.

    PubMed  Google Scholar 

  104. Zhu B, Liu JZ, Cauley SF, Rosen BR, Rosen MS. Image reconstruction by domain-transform manifold learning. Nature. 2018;555:487.

    PubMed  CAS  Google Scholar 

  105. Cohen O, Zhu B, Rosen MS. MR fingerprinting deep RecOnstruction NEtwork (DRONE). Magn Reson Med. 2018;80:885–94.

    PubMed  PubMed Central  Google Scholar 

  106. Avendi MR, Kheradvar A, Jafarkhani H. A combined deep-learning and deformable-model approach to fully automatic segmentation of the left ventricle in cardiac MRI. Med Image Anal. 2016;30:108–19.

    PubMed  CAS  Google Scholar 

  107. Oktay O, Ferrante E, Kamnitsas K, Heinrich M, Bai W, Caballero J, et al. Anatomically constrained neural networks (ACNNs): application to cardiac image Enhancement and segmentation. IEEE Trans Med Imaging. 2018;37:384–95.

    PubMed  Google Scholar 

  108. Larroza A, López-Lereu MP, Monmeneu JV, Gavara J, Chorro FJ, Bodí V, et al. Texture analysis of cardiac cine magnetic resonance imaging to detect nonviable segments in patients with chronic myocardial infarction. Med Phys. 2018;45:1471–80.

    PubMed  CAS  Google Scholar 

  109. Nazarian S, Hansford R, Rahsepar AA, Weltin V, McVeigh D, Gucuk Ipek E, et al. Safety of magnetic resonance imaging in patients with cardiac devices. N Engl J Med. 2017;377:2555–64.

    PubMed  PubMed Central  Google Scholar 

  110. Dill T. Contraindications to magnetic resonance imaging. Heart. 2008;94:943–8.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cleveland Clinic, Heart and Vascular Institute, Cleveland, OH, USA

    Ramya Vajapey MD, Brendan Eck PhD, Wilson Tang MD & Deborah H. Kwon MD

  2. Department of Cardiovascular Medicine, Cleveland Clinic, Imaging Institute, 9500 Euclid Avenue, Desk J1-5, Cleveland, OH, 44195, USA

    Deborah H. Kwon MD

Authors
  1. Ramya Vajapey MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brendan Eck PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wilson Tang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Deborah H. Kwon MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deborah H. Kwon MD.

Ethics declarations

Conflict of Interest

Ramya Vajapey, Brendan Eck, and Deborah H. Kwon each declare no potential conflicts of interest.

Wilson Tang is a section editor for Current Treatment Options in Cardiovascular Medicine.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Heart Failure

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vajapey, R., Eck, B., Tang, W. et al. Advances in MRI Applications to Diagnose and Manage Cardiomyopathies. Curr Treat Options Cardio Med 21, 74 (2019). https://doi.org/10.1007/s11936-019-0762-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11936-019-0762-z

Keywords

Search

Navigation